Abound Bio | Papers


Latest Articles and Papers


Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models

Featuring: Dimiter Dimitrov, PhD, ScD


Developability Assessment of an Isolated CH2 Immunoglobulin Domain

Featuring: Dimiter Dimitrov, PhD, ScD


Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection


High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models


Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Featuring: Dimiter Dimitrov, PhD, ScD


One small part of a human antibody has the potential to work as a drug for both prevention and therapy of COVID-19


Interaction with CD68 and Regulation of GAS6 Expression by Endosialin in Fibroblasts Drives Recruitment and Polarization of Macrophages in Hepatocellular Carcinoma

Featuring: Dimiter Dimitrov, PhD, ScD


Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

Featuring: Dimiter Dimitrov, PhD, ScD


Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model

Featuring: Dimiter Dimitrov, PhD, ScD

Kurt Gehlsen

Consultant, Strategic and Business Development

Highly experienced senior executive with 30+ year’s experience in private and public companies, company formation and growth, technology and company investments, pharmaceutical and medical device product development, basic research, clinical development, regulatory affairs, strategic planning, business development, licensing, project management, investor relations and executive management.